<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580733</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0007</org_study_id>
    <nct_id>NCT03580733</nct_id>
  </id_info>
  <brief_title>Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis</brief_title>
  <acronym>CASPER</acronym>
  <official_title>Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of intra-abdominal candidiasis is increasing, and it is now the leading
      indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of
      antifungal therapy have almost exclusively concerned patients with candidemia and did not
      include patients with intra-abdominal infections. The aim of this study is to demonstrate
      that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is
      associated with lower failure rate compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of intra-abdominal candidiasis is increasing, and it is now the leading
      indication for antifungal therapy, ahead of candidemia. These infections are clearly
      associated with increased morbidity and mortality in both community-acquired and
      healthcare-associated infections. So far,prospective randomized trials of antifungal therapy
      have almost exclusively concerned patients with candidemia and did not include patients with
      intra-abdominal infections. No prospective randomized trial has been conducted on
      intra-abdominal candidiasis and most retrospective analyses have reported very conflicting
      results concerning the impact of treatment on outcome. The aim of this study is therefore to
      demonstrate that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU
      patients is associated with lower failure rate compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">October 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure rate after the beginning of treatment</measure>
    <time_frame>28 days</time_frame>
    <description>28-day failure rate after the beginning of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 and 90 days</time_frame>
    <description>28 and 90-day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success rate at the end of treatment</measure>
    <time_frame>8 days</time_frame>
    <description>success rate at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>slope of ß-D-glucan concentrations</measure>
    <time_frame>8 days</time_frame>
    <description>slope of ß-D-glucan concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28- 28 day mortality for subgroup analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>ICU Yeast Intra-abdominal Infection</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antifungal therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caspofungin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin antifungal therapy</intervention_name>
    <description>caspofungin</description>
    <arm_group_label>antifungal therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Covered by national health insurance

          -  Admitted to ICU after surgery for intra-abdominal infection :

               -  With suspected intra-abdominal candidiasis defined by a Peritonitis score ≥ 3(1)

               -  Or with documented intra-abdominal candidiasis defined by positive direct
                  examination or positive culture of peritoneal fluid collected intraoperatively.

          -  With written and signed informed consent

        Exclusion Criteria:

          -  Allergy to caspofungin

          -  Life expectancy ≤ 48h

          -  Expected withdrawal of treatment

          -  Radiological drainage without surgery

          -  Severe hepatic impairment (Child-Pugh C score)

          -  Pregnant or lactating women

          -  Immunodepression (treatment including long-term corticosteroids, anti-TNF or disease
             including transplant patients)

          -  Infected acute pancreatitis

          -  Ascites fluid infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hervé Dupont, PD</last_name>
    <phone>33 322 087 979</phone>
    <email>dupont.herve@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hervé Dupont</last_name>
    <phone>33 322 087 979</phone>
    <email>dupont.herve@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Herve Dupont</last_name>
      <phone>33 322 087 979</phone>
      <email>dupont.herve@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU</keyword>
  <keyword>yeast intra abdominal infection</keyword>
  <keyword>candidiasis</keyword>
  <keyword>ß-D-glucan</keyword>
  <keyword>caspofungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

